# Alliance Pharma Plc A transformational year driving growth

- Link: https://www.directorstalkinterviews.com/alliance-pharma-plc-transformational-year-driving-growth/412729707
- Published: 2017-05-25T07:33:23+01:00
- Author: Giles Arbor

**[⌊Hardman & Co Report Report Downloads⌉⌊Hardman & Co Report Report Downloads⌉[Alliance Pharma
Plc** (LON:APH) buy-and-build strategy to evolve into a profitable, cash generative,
specialty pharma business is clearly bearing fruit. Acquisition of the dermatology
and woundcare products from Sinclair Pharma was transformational, doubling the size
of the company and providing a more internationally-oriented business. The enlarged
group is also a more attractive and credible partner for in–licensing and M&A opportunities.
2017 looks set to be an exciting year for the group: not only is there solid underlying
growth potential in the re-focused group, but also regulatory approval of Diclectin
offers further significant growth potential.

 

**Strategy:** Since inauguration, APH has adopted a buy-and-build model, with 33
deals over 19 years assembling a portfolio of >90 products and establishing a strong
track record. It is accelerating growth through investing in three multi-market 
brands, with infrastructure supported by its passive products.

**2016 results:** Reported sales of £97.5m were boosted by acquired products and
forex, with underlying growth of +7.4%. Gross margins were lower largely due to 
the acquired portfolio. Weak sterling negatively impacted net debt to -£76.1m; loan
reduction in 2017 will benefit from cash from the Sinclair warranty.

**Growth brands:** About half of marketing spend is focused on key international
growth brands: Kelo-Cote became APH’s first product to pass the £10m sales mark;
strong growth also seen with MacuShield; and once approved in UK and EU, Diclectin
is also expected to become an ‘International Star’ brand.

**Risks:** Alliance Pharma has a diversified strategy that includes International
Star brand growth potential supported by Bedrock products. However, as demonstrated
with Kelo-stretch, established sales patterns are not guaranteed, and the newly 
in-licensed Diclectin is an unknown entity.

**Investment summary:** Although APH is forecast to have +8% CAGR in sales over 
the next three years, medium-term EPS growth will be held back by the investment
in marketing. The progressive dividend policy is expected to remain. Shares are 
trading on a 2017 P/E of 11.6x and carry a dividend yield of 2.7%, covered 3.2x.
Launch of Diclectin has the potential to transform medium- to long-term growth prospects(
only UK launch costs included in current forecasts).

Share on:
